Better known by Novo Nordisk's brand names Ozempic and Wegovy (the former of which is indicated only for type 2 diabetes), ...

Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral density loss.

Studies also show that incretin-based therapies like Wegovy and Mounjaro are much less effective ... In 2023, Embark Biotech was acquired by Novo Nordisk to develop next generation therapeutics for ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

In addition to studies of experimental drugs, Lilly is testing its Zepbound against Novo Nordisk’s Wegovy in a head-to-head ...

Also worth noting, the trial did not involve titration—a dose increase period currently required for Eli Lilly’s Zepbound and ...

Diabetes and weight-loss drug tirzepatide (Mounjaro, Zepbound) was listed as a contributing factor in the death of a 58-year-old nurse from Scotland who died of multiple organ failure, septic shock, ...

If you said diabetes, you're right -- a new study finds diabetes costs $101 billion annually in diagnosis and treatment and ...

JPMorgan placed shares of Novo Nordisk (NVO) on “Positive Catalyst Watch” ahead of the CagriSema REDEFINE 1 obesity data. The ...

Analyst Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report) and keeping the price target at ...